Copyright © Inderes 2011 - present. All rights reserved.

Carasent

23.05 SEK

-1.07 %

1,644 following

CARA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

-1.07 %
-9.43 %
-16.03 %
-16.18 %
-14.63 %
-3.70 %
+51.57 %
-34.74 %
+4.22 %

Carasent is an IT company. The company delivers products and services within communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security and backup solutions. Customers are mainly found within health and care, finance and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

Read more
Market cap
1.67B SEK
Turnover
4.64M SEK
Revenue
343.82M
EBIT %
2.74 %
P/E
46.1
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14/4
2026

Interim report Q1'26

20/4
2026

General meeting '26

10/7
2026

Interim report Q2'26

ShowingAll content types
Third party research

Carasent: Är vändpunkten nådd? - Investera mera

Från ett spretigt bygge till en skalbar SaaS-maskin – Carasents historik och tidigare svaga sentiment har skapat en omotiverad rabatt i värderingen. https://www.investeramera.se/analyser/carasent-ar-vandpunkten-nadd

Carasent

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Carnegielta commissioned research pre-Q4 Inderes Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -... Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie...
1/29/2025, 6:41 AM
by timontti
6
redeye.se Carasent (Q3 Review): In good shape for exciting 2026 Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha Carasent’s profitability...
10/16/2025, 3:46 PM
by Diviner
2
I have thousands of euros worth of Carasent ASA. It is no longer traded, so I am stuck with the shares. I thought there would have been an automatic exchange to Carasent AB… Is anyone else in the same situation? What should I do? How can I prevent this in the future?
6/23/2025, 7:38 AM
by Loue
1
redeye.se Carasent: Back in Shape in 2024 – More to Come Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised New Base Case SEK28 (NOK26...
2/17/2025, 6:47 AM
by timontti
1
Redeye expectations for the Q1 report on Feb 13th
2/6/2025, 3:08 PM
by timontti
1
Inderes First day of trading in Carasent AB (publ) on Nasdaq Stockholm - Inderes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND...
12/9/2024, 9:27 AM
by timontti
1
Which intermediary? Contact them, and the matter should be resolved.
6/23/2025, 1:51 PM
by Turskanpyytäjä
0
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.